Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

SYNVISC ONE

Compare SYNVISC ONE  to:
Compare
Compare

Generic Name for SYNVISC ONE

Hylan G-F 20 (hylan A and hylan B) 48mg; per 6mL; soln for intra-articular inj.

Legal Classification:

Rx

Pharmacological Class for SYNVISC ONE

Hyaluronan derivative.

Manufacturer of SYNVISC ONE

Genzyme Corporation

Indications for SYNVISC ONE

Treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).

Adult dose for SYNVISC ONE

Remove synovial fluid or effusion before inj. Give as a single intra-articular inj. 6mL in one knee only.

Children's dosing for SYNVISC ONE

Not recommended.

Contraindications for SYNVISC ONE

Knee joint infections. Skin diseases or infections in area of inj site.

Warnings/Precautions for SYNVISC ONE

Avian protein, feathers, or egg allergy. Severely inflamed knee joints. Lymphatic or venous stasis in leg. Avoid strenuous activities for approx. 48 hrs following inj. Pregnancy, nursing mothers: not established.

Interactions for SYNVISC ONE

Avoid use of disinfectants containing quaternary ammonium salts; hyaluronan can precipitate in their presence. Concomitant other intra-articular inj: not studied.

Adverse Reactions for SYNVISC ONE

Arthralgia, arthritis, arthropathy, inj site pain, gait disturbance; joint effusion, stiffness, swelling, warmth, pain.

How is SYNVISC ONE supplied?

Single-use syringe—1

Related Disease:

Osteoarthritis

Related Resources

Diclofenac Sodium 1% Gel Safe for Long-Term Treatment of Osteoarthritis in Elderly

May 19, 2012

Diclofenac sodium 1% gel is well tolerated for up to 1 year for the relief of osteoarthritis (OA) pain in patients both <65 years and ≥65 years of age, according to 12-month data presented at the American Pain Society's 31st Annual Scientific Meeting.

Gender, High DAS28-P Index Predictive of Pain in Early RA

May 18, 2012

For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness and visual analog score) (DAS28-P) at baseline are predictive of less improvement in pain at one year.

Diclofenac Sodium 1% Gel Minimizes Drug-Drug Interaction-Related Adverse Events

May 17, 2012

Minimal systemic distribution of topical diclofenac sodium gel resulted in a lower incidence of major or moderate drug-drug interactions associated with oral diclofenac and reduced the risk of drug interaction-related adverse events. Study results were reported by Matthew Wieman, MD, from Endo Pharmaceuticals, John H. Peniston, DO, from Novartis Consumer Health, and colleagues at the American Pain Society's 31st Annual Scientific Meeting.

Vitamin D Deficiency Associated With Increased Osteoarthritis Symptoms and Reduced Pain Threshold

May 17, 2012

Study investigators presented data from the UPLOAD (Understanding Pain & Limitations in OsteoArthritic Disease) study at the American Pain Society's 31st Annual Scientific Meeting demonstrating that hydroxyvitamin D levels <25ng/mL were associated with an increase in osteoarthritis (OA) symptoms and a decreased threshold for pressure pain.

High Infection Rates Seen in Juvenile Idiopathic Arthritis

May 09, 2012

Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without the condition, and high-dose steroids significantly increase the rate of infection.

ANSAID

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Flurbiprofen 50mg, 100mg; tabs.

CIMZIA

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Certolizumab pegol 200mg/mL soln for SC inj; or per vial (pwd for SC inj after reconstitution); preservative-free.

Updated: 3/16/2012

EUFLEXXA

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Sodium hyaluronate 10mg/mL; soln for intra-articular inj.

Updated: 2/15/2012

HUMIRA

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Adalimumab 20mg/0.4mL, 40mg/0.8mL; soln for SC inj; preservative-free.

Updated: 3/19/2012

PREVACID NAPRAPAC 500

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Lansoprazole 15mg (7 caps containing e-c granules) + naproxen 500mg (14 tabs); per weekly blister card.

ANGELIQ 0.25/0.5

Ob/Gyn > Menopause and HRT

Monograph added.

Updated: 5/23/2012

 

ASTELIN

Respiratory Tract > Rhinitis/rhinorrhea (intranasal products)

Adverse reactions updated.

Updated: 5/8/2012

 

ATRAPRO ANTIPRURITIC HYDROGEL

Dermatological Disorders > Pruritus and dry skin

Monograph added.

Updated: 4/25/2012

 

ATRAPRO DERMAL SPRAY

Dermatological Disorders > Pressure/neuropathic ulcers

Monograph added.

Updated: 4/24/2012

 

B-NEXA

Nutrition > Vitamins/minerals/supplements

Monograph added.

Updated: 4/30/2012

 

Musculoskeletal Disorders > Arthritis/rheumatic disorders

NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDs): Osteoarthritis, rheumatoid arthritis, and related disorders are inflammatory conditions that induce the production and release of ...
more »

Arthritis Treatments: NSAIDS

January 12, 2012

NSAIDS (Non-steroidal anti-inflammatory drugs) indicated for the treatment of arthritis.

Arthritis Treatments: DMARDs and Other Immune Modulators

October 03, 2011

Dosing of DMARDS, TNF blockers, interleukin-1 receptor antagonists, interleukin-6 receptor inhibitors, selective costimulation modulators and CD20 antibodies for the treatment of arthritis.

Potentially Inappropriate Drugs for the Elderly (Beers List)

May 21, 2012

A list of drugs that may potentially be inappropriate for use in elderly patients due to their side effects. A description of the possible side effects is indicated next to each drug.

Osteoporosis Treatments

May 16, 2012

Osteoporosis treatment chart.

Mood Disorder Treatments

May 16, 2012

Mood disorder treatments for bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others.

ClinicalJobAdvisor

Loading...

More Jobs

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions